Bharat Biotech Covaxin efficacy 77.8 percent, gets CDSCO panel okay

Published On 2021-06-23 07:30 GMT | Update On 2021-06-23 09:45 GMT

New Delhi: An expert panel of the country's central drugs authority has reviewed and accepted the phase-3 trial data of Bharat Biotech's COVID-19 vaccine Covaxin, sources said on Tuesday.

According to the data submitted by the Hyderabad-based firm, the indigenously developed vaccine has shown 77.8 per cent efficacy in the trial conducted on 25,800 subjects, they said.

The firm had submitted the results of its phase-3 trial efficacy data of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, they added.

The COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday reviewed the data and accepted it. Their recommendations have been sent to the DCGI now, a source said.

Also Read:Bharat Biotech submits Covaxin phase 3 trial data to DCGI: Report

Bharat Biotech is also expected to attend a 'pre-submission' meeting on July 23 with the World Health Organisation (WHO), which will take the vaccine-maker closer to a WHO Emergency Use Listing (EUL).

Though the meeting will not be a detailed review on the product, the vaccine-maker will have an opportunity to submit a summary on the overall quality of the jab, according to the WHO.

The information was provided on the WHO website in the Status of COVID-19 Vaccines within WHO EUL-PQ evaluation process document.

Covaxin is one of the three vaccines approved by the DGCI for emergency use and is being deployed in India's COVID-19 vaccination programme.

Also Read:Bharat Biotech, WHO pre-submission meeting for Covaxin EUL on June 23

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medical Dialogues Team

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bharat Biotech Covaxin efficacy 77.8 percent, gets CDSCO panel okay

Similar News

After Cough Syrup Deaths, CDSCO Tightens Oversight on Drug Testing Compliance

Exemed Pharma's Empagliflozin-Vildagliptin Combo Rejected by CDSCO Panel Over Questionable Clinical Use

Ravenbhel Gets SEC Nod to Market Bilastine, Montelukast FDC, Phase IV Trial Mandated

Drugs Control Officials Caught Taking Rs 20,000 Bribe in Telangana

Contaminated Cough Syrup horror: Centre proposes license cancellation of Coldrif maker, Tamil Nadu FDA yet to act

Himachal, UP Join States Banning Coldrif Cough Syrup After MP Deaths

Toxic syrup tragedy: MP police hunt pharma co owner after child deaths

Not of Standard Quality: Gujarat orders suspension of production at two pharma cos